Perindopril in patients with myocardial infarction – experience of the Warsaw center Case report
Article Sidebar
Main Article Content
Abstract
A brief summary of data on the incidence of acute myocardial infarction and the prognosis of patients in Poland is presented. Due to the effect on prognosis, a key component of acute coronary syndrome therapy is early (within 24 h) introduction of angiotensin converting enzyme inhibitors (ACE-I), especially in patients with heart failure, left ventricular dysfunction, diabetes mellitus or infarct of the anterior wall. The distinguishing drug of this group is perindopril. It is characterized by a metabolite with a long half-life (17 h). It is suggested that perindopril has pleiotropic properties, i.e. by affecting atherosclerotic plaque and improvement of left ventricular function, which translates into beneficial effects in the prevention of cardiovascular events. Two examples of the use of perindopril in patients after myocardial infarction is presented.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg P.G., James S.K., Atar D. et al.: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012; 33(20): 2569-2619.
3. Savarese G., Costanzo P., Cleland J.G. et al.: A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J. Am. Coll. Cardiol. 2013; 61(2): 131-142.
4. Fox K.M., Bertrand M.E., Remme W.J. et al.: Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. Am. Heart J. 2007; 153(4): 629-635.
5. Remme W.J., Deckers J.W., Fox K.M. et al.: Secondary prevention of coronary disease with ACE inhibition – does blood pressure reduction with perindopril explain the benefits in EUROPA? Cardiovasc. Drugs Ther. 2009; 23(2): 161-170.
6. Ceconi C., Francolini G., Olivares A. et al.: Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. 2007; 577(1-3): 1-6.
7. Nearchou N.S., Tsakiris A.K., Lolaka M.D. et al.: Influence of perindopril on left ventricular global performance during the early phase of inferior acute myocardial infarction: assessment by Tei index. Echocardiography 2003; 20(4): 319-327.
8. Ferrari R.; Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators: Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch. Intern. Med. 2006; 166(6): 659-666.
9. Nicolosi G.L., Golcea S., Ceconi C. et al.: Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-study. Eur. Heart J. 2009; 30(13): 1656-1665.
10. Piepoli M.F., Hoes A.W., Agewall S. et al.; 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. J. Prev. Cardiol. 2016; 23(11): NP1-NP96.
11. Cleland J.G., Tendera M., Adamus J. et al.: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 2006; 27(19): 2338-2345.